# Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma

> **NCT03383978** · PHASE1 · RECRUITING · sponsor: **Johann Wolfgang Goethe University Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** NK-92/5.28.z
- **DRUG:** Ezabenlimab

## Key facts

- **NCT ID:** NCT03383978
- **Lead sponsor:** Johann Wolfgang Goethe University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383978, "Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03383978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*